FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377019080> ?p ?o ?g. }

• W4377019080 endingPage "D28" @default.
• W4377019080 startingPage "D28" @default.
• W4377019080 abstract "Abstract Introduction Transthyretin–mediated (ATTR) amyloidosis is a progressive, multisystem, fatal disease. Patisiran, an IV RNAi therapeutic, is approved for the treatment of hereditary ATTR amyloidosis with polyneuropathy. The safety and efficacy of patisiran in patients with wild–type or hereditary ATTR amyloidosis with cardiomyopathy (CM) is being investigated in the ongoing APOLLO–B study. Methods Patients were 18–85 yrs old with evidence of cardiac amyloidosis by echocardiography, and ATTR amyloid by tissue biopsy or fulfilling nonbiopsy diagnostic criteria for ATTR amyloidosis with CM. Medical history of heart failure (HF) due to ATTR amyloidosis with ≥1 prior hospitalization or current clinical evidence of HF was required. Patients were randomized 1:1 to patisiran IV 0.3 mg/kg or placebo Q3W for 12 months. The primary endpoint was change from baseline in 6–MWT at Month 12 (M12) with patisiran vs placebo. Results APOLLO–B enrolled 360 patients (patisiran, n=181; placebo, n=179): median age (range), 76.0 (41, 85) yrs; male, 89%; wtATTR, 80%. Baseline characteristics were consistent between patients on tafamidis at baseline (91/360 [25%]) and those who were not. Patisiran achieved a rapid and sustained reduction in serum TTR, irrespective of baseline tafamidis treatment. At M12, patisiran showed a significant benefit vs placebo in 6–MWT (median [95% CI] change from baseline: patisiran, –8.15 [–16.42, 1.50]; placebo, –21.35 [–34.05, –7.52]; HL estimate of median difference: 14.69 [0.69, 28.69]; p=0.0162) and KCCQ–OS (LS mean [SEM] change from baseline: patisiran, 0.300 [1.263]; placebo, –3.408 [1.277]; LS mean [SEM] difference: 3.709 [1.796]; p=0.0397). Consistent benefits with patisiran in 6–MWT and KCCQ–OS were observed across predefined patient subgroups. Time to first event of all–cause hospitalization, urgent HF visit, or death directionally favored patisiran vs placebo (HR [95% CI], 0.839 [0.557, 1.263]), as did all–cause mortality (HR [95% CI], 0.355 [0.110, 1.138]), but all composite outcomes endpoints did not achieve statistical significance over 12 months. Patisiran was well tolerated; most AEs were mild or moderate in severity, and there were no cardiac safety concerns. Conclusions Benefits at 12 months were observed with patisiran vs placebo in functional capacity, and health status and quality of life, in patients with ATTR amyloidosis with CM. The efficacy and safety of patisiran continues to be studied in the APOLLO–B open–label extension." @default.
• W4377019080 created "2023-05-19" @default.
• W4377019080 creator A5000612349 @default.
• W4377019080 creator A5000758389 @default.
• W4377019080 creator A5009799168 @default.
• W4377019080 creator A5010380434 @default.
• W4377019080 creator A5015330548 @default.
• W4377019080 creator A5015350489 @default.
• W4377019080 creator A5015586149 @default.
• W4377019080 creator A5023001769 @default.
• W4377019080 creator A5025035201 @default.
• W4377019080 creator A5033756615 @default.
• W4377019080 creator A5043049060 @default.
• W4377019080 creator A5046447536 @default.
• W4377019080 creator A5050125018 @default.
• W4377019080 creator A5050388463 @default.
• W4377019080 creator A5052148639 @default.
• W4377019080 creator A5057365396 @default.
• W4377019080 creator A5059064031 @default.
• W4377019080 creator A5059417970 @default.
• W4377019080 creator A5070623406 @default.
• W4377019080 creator A5072181166 @default.
• W4377019080 creator A5072877047 @default.
• W4377019080 creator A5081059143 @default.
• W4377019080 creator A5083202936 @default.
• W4377019080 creator A5090968979 @default.
• W4377019080 date "2023-05-01" @default.
• W4377019080 modified "2023-10-01" @default.
• W4377019080 title "C66 PRIMARY RESULTS FROM APOLLO–B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN–MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY" @default.
• W4377019080 doi "https://doi.org/10.1093/eurheartjsupp/suad111.065" @default.
• W4377019080 hasPublicationYear "2023" @default.
• W4377019080 type Work @default.
• W4377019080 citedByCount "0" @default.
• W4377019080 crossrefType "journal-article" @default.
• W4377019080 hasAuthorship W4377019080A5000612349 @default.
• W4377019080 hasAuthorship W4377019080A5000758389 @default.
• W4377019080 hasAuthorship W4377019080A5009799168 @default.
• W4377019080 hasAuthorship W4377019080A5010380434 @default.
• W4377019080 hasAuthorship W4377019080A5015330548 @default.
• W4377019080 hasAuthorship W4377019080A5015350489 @default.
• W4377019080 hasAuthorship W4377019080A5015586149 @default.
• W4377019080 hasAuthorship W4377019080A5023001769 @default.
• W4377019080 hasAuthorship W4377019080A5025035201 @default.
• W4377019080 hasAuthorship W4377019080A5033756615 @default.
• W4377019080 hasAuthorship W4377019080A5043049060 @default.
• W4377019080 hasAuthorship W4377019080A5046447536 @default.
• W4377019080 hasAuthorship W4377019080A5050125018 @default.
• W4377019080 hasAuthorship W4377019080A5050388463 @default.
• W4377019080 hasAuthorship W4377019080A5052148639 @default.
• W4377019080 hasAuthorship W4377019080A5057365396 @default.
• W4377019080 hasAuthorship W4377019080A5059064031 @default.
• W4377019080 hasAuthorship W4377019080A5059417970 @default.
• W4377019080 hasAuthorship W4377019080A5070623406 @default.
• W4377019080 hasAuthorship W4377019080A5072181166 @default.
• W4377019080 hasAuthorship W4377019080A5072877047 @default.
• W4377019080 hasAuthorship W4377019080A5081059143 @default.
• W4377019080 hasAuthorship W4377019080A5083202936 @default.
• W4377019080 hasAuthorship W4377019080A5090968979 @default.
• W4377019080 hasBestOaLocation W43770190801 @default.
• W4377019080 hasConcept C121157162 @default.
• W4377019080 hasConcept C126322002 @default.
• W4377019080 hasConcept C141071460 @default.
• W4377019080 hasConcept C142724271 @default.
• W4377019080 hasConcept C203092338 @default.
• W4377019080 hasConcept C204787440 @default.
• W4377019080 hasConcept C27081682 @default.
• W4377019080 hasConcept C2775892965 @default.
• W4377019080 hasConcept C2777607188 @default.
• W4377019080 hasConcept C2778198053 @default.
• W4377019080 hasConcept C2778797674 @default.
• W4377019080 hasConcept C2779951007 @default.
• W4377019080 hasConcept C535046627 @default.
• W4377019080 hasConcept C71924100 @default.
• W4377019080 hasConcept C90924648 @default.
• W4377019080 hasConceptScore W4377019080C121157162 @default.
• W4377019080 hasConceptScore W4377019080C126322002 @default.
• W4377019080 hasConceptScore W4377019080C141071460 @default.
• W4377019080 hasConceptScore W4377019080C142724271 @default.
• W4377019080 hasConceptScore W4377019080C203092338 @default.
• W4377019080 hasConceptScore W4377019080C204787440 @default.
• W4377019080 hasConceptScore W4377019080C27081682 @default.
• W4377019080 hasConceptScore W4377019080C2775892965 @default.
• W4377019080 hasConceptScore W4377019080C2777607188 @default.
• W4377019080 hasConceptScore W4377019080C2778198053 @default.
• W4377019080 hasConceptScore W4377019080C2778797674 @default.
• W4377019080 hasConceptScore W4377019080C2779951007 @default.
• W4377019080 hasConceptScore W4377019080C535046627 @default.
• W4377019080 hasConceptScore W4377019080C71924100 @default.
• W4377019080 hasConceptScore W4377019080C90924648 @default.
• W4377019080 hasIssue "Supplement_D" @default.
• W4377019080 hasLocation W43770190801 @default.
• W4377019080 hasOpenAccess W4377019080 @default.
• W4377019080 hasPrimaryLocation W43770190801 @default.
• W4377019080 hasRelatedWork W2053677156 @default.
• W4377019080 hasRelatedWork W2171770402 @default.
• W4377019080 hasRelatedWork W2589116914 @default.
• W4377019080 hasRelatedWork W2889143351 @default.
• W4377019080 hasRelatedWork W2896529812 @default.

• next